Education and decision-support only — not a medical device or personalised advice. Always discuss your specific situation with your specialist team.

Context

Melanoma can return after surgery. A 2026 single‑center study found circulating tumor DNA (ctDNA) was detectable a median 8 weeks before imaging showed relapse in 112 patients ¹.

Introduction

Imagine a blood test that warns you of a melanoma comeback before any scan can see it. This page explains how ctDNA works, when it can be useful, and what questions remain. It draws on eight peer‑reviewed studies—including a systematic review, a prospective monitoring trial, and two early‑phase immunotherapy papers—to reflect current evidence while noting ongoing uncertainties.

Can ctDNA Spot Melanoma Recurrence Earlier Than Imaging?

In a prospective cohort of 112 stage I–IIIB patients, ctDNA became positive a median of 8 weeks before radiologic evidence of relapse ¹. A separate analysis of early ctDNA dynamics during immune‑checkpoint inhibitor therapy reported that rising ctDNA levels preceded imaging findings by several weeks ². Both studies suggest blood‑based monitoring can flag disease before scans. The first study was single‑institution and modest in size, so its results may not apply to all patient groups. Larger, multi‑center trials are needed to confirm generalizability.
Practical tip: Ask your oncology team if a scheduled blood draw for ctDNA is part of your follow‑up plan, and whether the results will be reviewed alongside imaging.

Does ctDNA Predict Future Outcomes Like Recurrence or Death?

A 2026 systematic review and meta‑analysis of 31 studies linked post‑surgical ctDNA positivity to a three‑fold higher risk of recurrence and a 2.5‑fold higher risk of melanoma‑specific death ³. The authors noted moderate heterogeneity (I² ≈ 45 %) and possible publication bias from smaller studies. Supporting this, a nomogram built from longitudinal ctDNA kinetics predicted therapeutic resistance and poorer survival in metastatic melanoma ⁴. Together, the data show ctDNA can be a strong prognostic marker, yet variability across studies and potential bias temper confidence.
Practical tip: If ctDNA is detected after surgery, discuss with your oncologist whether more intensive surveillance or adjuvant therapy adjustments are advisable.

What Gaps Remain Before ctDNA Can Replace Standard Surveillance?

Early ctDNA monitoring during checkpoint‑inhibitor treatment can forecast response, but the optimal timing, assay sensitivity, and threshold for clinical action are still debated ². The resistance‑prediction nomogram, while promising, has been validated only in limited cohorts and needs testing in diverse populations ⁴. Moreover, no study has yet shown that ctDNA‑guided management improves overall survival compared with current imaging‑based protocols. These gaps highlight the need for larger randomized trials and standardized testing methods.
Practical tip: Keep a personal log of any ctDNA results you receive and share it with each new specialist, so trends can be interpreted in context.

What This Means for You

ctDNA testing offers a way to catch melanoma recurrence sooner than scans and may signal a higher chance of future disease. At present, it complements—not replaces—standard imaging and physical exams. Discuss with your dermatologist whether adding ctDNA monitoring fits your individual risk profile and treatment plan. Ask about the availability of the test, how often it would be done, and what actions might follow a positive result. Always discuss any changes to your care or screening plan with a qualified dermatologist.

TL;DR

  • ctDNA can appear in blood weeks before scans show melanoma recurrence.
  • Positive ctDNA after surgery predicts a higher risk of relapse and death.
  • Study sizes are small and results vary; more research is needed.
  • Talk to your dermatologist about adding ctDNA tests to your follow‑up schedule.
  • Ask how ctDNA results would change imaging frequency or treatment choices.

References

  1. 1.PMID:41632449pubmed.ncbi.nlm.nih.gov
  2. 2.PMID:41687044pubmed.ncbi.nlm.nih.gov
  3. 3.PMID:42107274pubmed.ncbi.nlm.nih.gov
  4. 4.PMID:41806257pubmed.ncbi.nlm.nih.gov